The approval of the first two monoclonal antibodies targeting CD38 (daratumumab) and
SLAMF7 (elotuzumab) in late 2015 for treating relapsed and refractory multiple myeloma …

B-cell activation factor from the tumor necrosis factor family (BAFF) is a key survival factor
during B-cell maturation—a delicate immune checkpoint for B cells. Excessive BAFF …

B-cell maturation antigen (BCMA) is an attractive therapeutic target highly expressed on
differentiated plasma cells in multiple myeloma and other B-cell malignancies. GSK2857916 …

Although TNFRSF 17 (also designated as B‐cell maturation antigen (BCMA)) is expressed
on tumour cells in B‐cell malignancies, it has not been found in serum. The present study …

Hodgkin lymphoma (HL) originates from the clonal expansion of malignant Hodgkin and
Reed-Sternberg (HRS) cells. These B-cell–derived elements constitute less than 10% of the …

Recent studies have underscored the role of B-cell-activating factor (BAFF), a member of the
tumor necrosis factor superfamily, in promoting the survival of malignant B cells, including …

Chimeric antigen receptor (CAR) technology has revolutionized cancer treatment,
particularly in malignant hematological tumors. Currently, the BCMA-targeted second …

In the past 36 months, new developments have occurred both in the understanding of the
biology of Waldenström macroglobulinemia (WM) and in therapeutic options for WM. Here …

One remarkable feature of the immune system is its capacity to maintain constant numbers
of resting immune cells despite the complex nature of signals needed throughout …

B cells require signals from multiple sources for their development from precursor cells, and
differentiation into effector cells. BAFF has been identified as a critical regulator of B cell …